N-(1-adamantyl)-2-{3-[(2R)-2-({(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide | 864153-25-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(1-adamantyl)-2-{3-[(2R)-2-({(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide
• 英文别名: N-1-adamantyl-2-{3-[(2R)-2-({(2R)-2-{[tert-butyl(dimethyl)sily]oxy}-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide；N-(1-adamantyl)-2-[3-[(2R)-2-[[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl]amino]propyl]phenyl]acetamide
• CAS: 864153-25-3
• 化学式: C₃₆H₅₄N₂O₄Si
• 分子量: 606.921
• InChiKey: YRVDZGAEQXMFDJ-YJQHTRGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  43
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  90.8
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-(1-adamantyl)-2-{3-[(2R)-2-({(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide 在 triethylamine tris(hydrogen fluoride) 作用下， 以 四氢呋喃 为溶剂， 反应 24.0h， 生成 N-1-Adamantanyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)-phenyl]ethyl}amino)propyl]phenyl}acetamide
  参考文献：
  名称：

  L-tartrate salt of N-1-Adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl] phenyl}acetamide

  摘要：

  这项发明涉及N-1-戊环基-2-{3-[(2R)-2-({(2R)-2-羟基-2-[4-羟基-3-(羟甲基)苯基]乙基}氨基)丙基]苯基}乙酰胺的L-酒石酸盐及其作为药物的用途。

  公开号：

  US20060106107A1
• 作为产物：
  描述：

  N-(1-adamantyl)-2-[3-[(2R)-2-[[(2R)-2-[tert-butyl(dimethyl)silyl]oxy-2-[3-(hydroxymethyl)-4-phenylmethoxyphenyl]ethyl]amino]propyl]phenyl]acetamide 在 palladium on activated charcoal 甲酸铵 作用下， 以 乙醇 为溶剂， 以100%的产率得到N-(1-adamantyl)-2-{3-[(2R)-2-({(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide
  参考文献：
  名称：

  The discovery of adamantyl-derived, inhaled, long acting β2-adrenoreceptor agonists

  摘要：

  The design and pro. le of a series of adamantyl-containing long acting beta(2)-adrenoreceptor agonists are described. An optimal pharmacokinetic profile of low oral bioavailability was combined with a strong pharmacology pro. le when assessed using a guinea pig trachea tissue model. A focus was then placed on developing a robust synthetic route to ensure rapid delivery of material for clinical trials. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.01.034

文献信息

• L-tartrate salt of N-1-Adamantyl-2-{3-[(2R)-2-({(2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl] phenyl}acetamide
  申请人：James Kim

  公开号：US20060106107A1

  公开（公告）日：2006-05-18

  This invention relates to the L-tartrate salt of N-1-Adamantyl-2-3-[(2R)-2-((2R)-2-hydroxy-2-[4-hydroxy-3-(hydroxymethyl)phenyl]ethyl}amino)propyl]phenyl}acetamide and its use as a medicament.

  这项发明涉及N-1-戊环基-2-3-[(2R)-2-((2R)-2-羟基-2-[4-羟基-3-(羟甲基)苯基]乙基}氨基)丙基]苯基}乙酰胺的L-酒石酸盐及其作为药物的用途。
• The discovery of adamantyl-derived, inhaled, long acting β2-adrenoreceptor agonists
  作者：Alan D. Brown、Mark E. Bunnage、Paul A. Glossop、Kim James、Rhys Jones、Charlotte A.L. Lane、Russell A. Lewthwaite、Simon Mantell、Christelle Perros-Huguet、David A. Price、Mike Trevethick、Rob Webster

  DOI：10.1016/j.bmcl.2008.01.034

  日期：2008.2

  The design and pro. le of a series of adamantyl-containing long acting beta(2)-adrenoreceptor agonists are described. An optimal pharmacokinetic profile of low oral bioavailability was combined with a strong pharmacology pro. le when assessed using a guinea pig trachea tissue model. A focus was then placed on developing a robust synthetic route to ensure rapid delivery of material for clinical trials. (c) 2008 Elsevier Ltd. All rights reserved.